Log In
BCIQ
Print this Print this
 

PDC*mel

  Manage Alerts
Collapse Summary General Information
Company PDC*line Pharma
DescriptionPlasmacytoid dendritic cell therapeutic vaccine composed of melan-A (MLANA; MART1), tyrosinase (oculocutaneous albinism IA; TYR), glycloprotein 100 (gp100) and melanoma-associated antigen A3 (MAGEA3)
Molecular Target Not applicable
Mechanism of ActionCell therapy
Therapeutic ModalityCell therapy: Non-stem cell
Latest Stage of DevelopmentPhase I
Standard IndicationMelanoma
Indication DetailsTreat melanoma
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today